Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?

Patients diagnosedwithmultiple myeloma (MM) have an increased venous thromboembolic event (VTE) risk. This risk increases in relation to the patient risk factors and the type of chemotherapy. The concept that immunomodulatory drugs (IMiDs) such as thalidomide and lenalidomide might significantly contribute to the increased risk of VTE is well recognized [1… CONTINUE READING